Last reviewed · How we verify
Mavacamten Capsule 3
At a glance
| Generic name | Mavacamten Capsule 3 |
|---|---|
| Also known as | BMS-986427, MYK-461 |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM (PHASE2, PHASE3)
- A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants (PHASE1)
- Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects (PHASE1)
- A Study to Evaluate the Effects of Mavacamten in Healthy Participants (PHASE1)
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants (PHASE1)
- A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mavacamten Capsule 3 CI brief — competitive landscape report
- Mavacamten Capsule 3 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI